These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36940723)

  • 1. AGEs RAGE Pathways: Alzheimer's Disease.
    Maheshwari S
    Drug Res (Stuttg); 2023 Jun; 73(5):251-254. PubMed ID: 36940723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.
    Prasad K
    Mol Cell Biochem; 2019 Sep; 459(1-2):95-112. PubMed ID: 31079281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.
    Fang F; Yu Q; Arancio O; Chen D; Gore SS; Yan SS; Yan SF
    Hum Mol Genet; 2018 Mar; 27(6):1002-1014. PubMed ID: 29329433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor for Advanced Glycation End Products: Dementia and Cognitive Impairment.
    Singh A; Ansari VA; Mahmood T; Ahsan F; Wasim R; Shariq M; Parveen S; Maheshwari S
    Drug Res (Stuttg); 2023 Jun; 73(5):247-250. PubMed ID: 36889338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term voluntary exercise inhibited AGE/RAGE and microglial activation and reduced the loss of dendritic spines in the hippocampi of APP/PS1 transgenic mice.
    Wang YY; Zhou YN; Jiang L; Wang S; Zhu L; Zhang SS; Yang H; He Q; Liu L; Xie YH; Liang X; Tang J; Chao FL; Tang Y
    Exp Neurol; 2023 May; 363():114371. PubMed ID: 36871860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's Disease.
    Ko SY; Ko HA; Chu KH; Shieh TM; Chi TC; Chen HI; Chang WC; Chang SS
    PLoS One; 2015; 10(11):e0143345. PubMed ID: 26587989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model.
    Guo C; Zhang S; Li JY; Ding C; Yang ZH; Chai R; Wang X; Wang ZY
    Sci Rep; 2016 Jul; 6():29396. PubMed ID: 27406855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice.
    Yin K; Jin J; Zhu X; Yu L; Wang S; Qian L; Han L; Xu Y
    Neurol Res; 2017 Oct; 39(10):885-894. PubMed ID: 28743230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology.
    Sakae N; Liu CC; Shinohara M; Frisch-Daiello J; Ma L; Yamazaki Y; Tachibana M; Younkin L; Kurti A; Carrasquillo MM; Zou F; Sevlever D; Bisceglio G; Gan M; Fol R; Knight P; Wang M; Han X; Fryer JD; Fitzgerald ML; Ohyagi Y; Younkin SG; Bu G; Kanekiyo T
    J Neurosci; 2016 Mar; 36(13):3848-59. PubMed ID: 27030769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Glycation End Products Modulate Amyloidogenic APP Processing and Tau Phosphorylation: A Mechanistic Link between Glycation and the Development of Alzheimer's Disease.
    Batkulwar K; Godbole R; Banarjee R; Kassaar O; Williams RJ; Kulkarni MJ
    ACS Chem Neurosci; 2018 May; 9(5):988-1000. PubMed ID: 29384651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RP1, a RAGE antagonist peptide, can improve memory impairment and reduce Aβ plaque load in the APP/PS1 mouse model of Alzheimer's disease.
    Huang YY; Fang N; Luo HR; Gao F; Zou Y; Zhou LL; Zeng QP; Fang SS; Xiao F; Zheng Q
    Neuropharmacology; 2020 Dec; 180():108304. PubMed ID: 32931813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-ribose and pathogenesis of Alzheimer's disease.
    Javed M; Ahmad MI; Javed H; Naseem S
    Mol Biol Rep; 2020 Mar; 47(3):2289-2299. PubMed ID: 31933261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide.
    Storey E; Cappai R
    Neuropathol Appl Neurobiol; 1999 Apr; 25(2):81-97. PubMed ID: 10215996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treadmill exercise attenuates Aβ burdens and astrocyte activation in APP/PS1 mouse model of Alzheimer's disease.
    Zhang J; Guo Y; Wang Y; Song L; Zhang R; Du Y
    Neurosci Lett; 2018 Feb; 666():70-77. PubMed ID: 29246793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment.
    Gasparotto J; Girardi CS; Somensi N; Ribeiro CT; Moreira JCF; Michels M; Sonai B; Rocha M; Steckert AV; Barichello T; Quevedo J; Dal-Pizzol F; Gelain DP
    J Biol Chem; 2018 Jan; 293(1):226-244. PubMed ID: 29127203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.